Clinical Monograph: Aqualyx (Aqueous Deoxycholic Acid Solution)

1. Classification and Chemical Overview

• Active Composition: Desoxycholic acid (also known as deoxycholic acid) derivative formulated into an aqueous, biocompatible, slow-release micro-gel system (often incorporating 3,712-alpha-dihydroxy-5-beta-choland-24-oic acid sodium salt).

• Therapeutic Class: Lipolytic agent / Adipocytolytic injectable / Non-surgical body contouring compound.

• Regulatory Status: Professional-use medical device (CE-marked in Europe), administered exclusively by trained medical or aesthetic practitioners utilizing specialized injection techniques (such as the Cavi-Lipo / Lipo-inject or Fan technique).

2. Mechanism of Action and Pharmacodynamics

• Adipocytolysis (Fat Cell Destruction): Deoxycholic acid is a secondary bile acid that acts as a cytolytic detergent. When injected directly into subcutaneous adipose tissue, it disrupts the cell membranes of adipocytes (fat cells), leading to cell lysis.

• Macrophage Clearance: Once the fat cell membranes rupture and release their triglyceride contents into the extracellular matrix, local inflammatory macrophages clear the cellular debris and lipids through natural lymphatic and metabolic elimination.

• Connective Tissue Contraction: The local micro-gel formulation induces a mild fibrotic reaction within the subcutaneous septae, which can promote tissue retraction and skin tightening as the localized fat volume decreases.

3. Approved Clinical Indications and Dosing Scope

• Indications:

  • Reduction of localized, stubborn subcutaneous fat deposits that are resistant to diet and exercise.

  • Common target areas include the submental region (chin), jowls, upper arms, flanks, abdomen, “buffalo hump,” and outer/inner thighs.

• Limitations of Use: Not indicated for systemic weight loss or obesity treatment; designed solely for localized pocket contouring.

• Dosing Regimen & Administration:

  • Administered via specialized blunt-tip cannulas or fine needles directly into the subcutaneous fat layer.

  • Typically requires a course of 2 to 6 treatment sessions, spaced approximately 3 to 4 weeks apart, depending on the volume of the targeted fat depot.

4. Pharmacokinetic Profile

• Local Retention: The micro-gel polymer matrix slows the immediate diffusion of the active compound, concentrating the lytic activity within the targeted adipose layer.

• Metabolism & Elimination: Released free fatty acids and glycerol are metabolized via normal physiological pathways. Deoxycholic acid is bound to plasma proteins, cleared by the liver, and excreted via bile and feces.

5. Physiological Effects and Adverse Event Spectrum

Localized inflammatory responses, swelling, and edema are expected physiological consequences of targeted fat cell lysis.

Adverse Reaction Profile

• Very Common / Common ($\ge 1/10$): Intense localized swelling, edema, erythema, bruising, tenderness, burning sensation, and moderate pain at the injection site lasting several days.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Temporary paresthesia, skin nodularity, induration, or mild contour irregularities as the tissue remodels.

• Rare / Severe (<1/1,000): Temporary marginal mandibular nerve injury (resulting in asymmetrical smile when treating submental fat), skin ulceration, localized necrosis secondary to superficial intradermal injection, or severe hypersensitivity reactions.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contra-indicaties

• Known hypersensitivity to deoxycholic acid or any formulation excipients.

• Pregnancy and breastfeeding.

• Active localized skin infections, inflammation, or rashes at the target treatment site.

• Severe systemic conditions, liver or kidney disease, or blood coagulation disorders.

Key Interacting Factors & Warnings

• Depth Precision: Aqualyx must be injected strictly into the subcutaneous fat layer. Intradermal injection can lead to skin sloughing, necrosis, or ulceration; accidental intramuscular injection can cause localized muscle damage.

• Aseptic Handling: Must be administered under strict sterile conditions using specialized injection cannulas to minimize vessel trauma.

Clinical Precautions and Post-Treatment Guidelines

• Post-Procedure Care: Advise patients to anticipate significant localized swelling for 48 to 72 hours post-treatment. Compression garments may be recommended for body areas (like the abdomen or thighs). Patients should avoid strenuous exercise, excessive heat (saunas), and alcohol for 24 to 48 hours to minimize secondary inflammation.